Loading…
Employees: 195
Size Jenscare Scientific (9877.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $463M, the 778th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$6.45 on 6 Nov 2026.
Performance Over six months the shares fell 32.2%, against -13.4% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 992.7% over the last twelve months (peer median +0.5%); the operating margin is -106.3% (peer median 8.6%).
Valuation It trades at 20.2× enterprise value to sales against a peer median of 4.4× (2nd most expensive of 20).
Capital Return on invested capital runs 43.1 points below its cost of capital (7.8% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$158M | HK$98.2M | HK$0 | HK$0 | HK$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | HK$121M | HK$74.6M | -HK$13.9M | -HK$13.3M | -HK$10.7M |
| EBITDA | -HK$147M | -HK$242M | -HK$222M | -HK$471M | -HK$584M |
| Net income | -HK$167M | -HK$294M | -HK$192M | -HK$411M | -HK$511M |
| Free cash flow | -HK$84.6M | -HK$86.2M | -HK$313M | -HK$332M | -HK$247M |
| Capital expenditure | HK$17.6M | HK$5.50M | HK$77.7M | HK$86.9M | HK$57.6M |
| Total debt | n/a | HK$52.8M | HK$68.6M | HK$48.5M | HK$4.35M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9877.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.9% | -6.0% | 5th lowest of 21 |
| 6-month return | -32.2% | -13.4% | 3rd lowest of 21 |
| Distance from 52-week high | -46.2% | -36.7% | 5th lowest of 21 |
| Revenue growth (TTM) | +992.7% | +0.5% | highest of 21 |
| Operating margin | -106.3% | 8.6% | 2nd lowest of 21 |
| EV / Sales | 20.2× | 4.4× | 2nd most expensive of 20 |
| ROIC minus cost of capital | -43.1 pp | -2.4 pp | 2nd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | 20.2× | n/a | n/a |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | 7.1× | 42.6% | +0.4% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 5.2× | 22.1% | +2.2% |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 1.5× | n/a | n/a |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | 3.5× | 6.7% | +0.3% |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 3.7× | 0.9% | +15.6% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | 4.0× | 22.2% | -11.7% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | 1.6× | 3.8% | -2.8% |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 1.6× | n/a | n/a |
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -1,178% | 410.3× | n/a | n/a |
| Brainsway Ltd Sponsored ADR BWAY | United States | $450M | -35% | +32% | 12% | 6.5× | 34.3% | +18.8% |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | n/a | n/a | n/a |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | 7.5× | 35.5% | -6.9% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 1.2× | 11.5% | +11.0% |
| Chison Medical Technologies 688358.SS | China | $443M | -16% | -1% | 19% | 4.4× | 11.8% | +5.6% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 6.0× | 6.5% | +10.0% |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 2.0× | -5.6% | +7.7% |
| Guanhao Biotech 300238.SZ | China | $440M | -25% | -7% | 5% | 7.8× | n/a | n/a |
| 908 Devices MASS | United States | $436M | +29% | +1% | -35% | 5.5× | n/a | n/a |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | 1.4× | n/a | n/a |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 5.5× | 19.3% | +12.4% |